<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">REMEDIUM</journal-id><journal-title-group><journal-title>REMEDIUM</journal-title></journal-title-group><issn publication-format="print">1561-5936</issn><issn publication-format="electronic">2658-3534</issn><publisher><publisher-name>Joint-Stock Company Chicot</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1158</article-id><article-id pub-id-type="doi">10.21518/1561-5936-2019-11-27-31</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Chronic vein diseases: a pressing issue of our time</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Beregovykh</surname><given-names>Roman</given-names></name><bio></bio><email>noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Prozherina</surname><given-names>Yuliya</given-names></name><bio></bio><email>noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">Remedium</aff><pub-date date-type="epub" iso-8601-date="2019-12-11" publication-format="electronic"><day>11</day><month>12</month><year>2019</year></pub-date><issue>11</issue><fpage>27</fpage><lpage>31</lpage><history><pub-date date-type="received" iso-8601-date="2022-03-18"><day>18</day><month>03</month><year>2022</year></pub-date></history><permissions><copyright-statement>Copyright © 2019,</copyright-statement><copyright-year>2019</copyright-year></permissions><abstract>Circulatory system diseases remain a challenging medical and social problem for the world's population: prevalence, clinical features and consequences of these diseases largely determine the decline in human life quality and expectancy [1]. Chronic venous diseases (CVD) take a special place in this group of pathologies to which young people are increasingly exposed. In this regard, timely prevention and effective treatment of CVD, especially at the early stages, are of prime importance.</abstract><kwd-group xml:lang="en"><kwd>chronic vein diseases</kwd><kwd>prevention</kwd><kwd>treatment</kwd><kwd>flavonoids</kwd><kwd>diosmin and hesperidin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хронические заболевания вен</kwd><kwd>профилактика</kwd><kwd>лечение</kwd><kwd>флавоноиды</kwd><kwd>диосмин и гесперидин</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Бойцов С.А., Самородская И.В. Смертность и потерянные годы жизни в результате преждевременной смертности от болезней системы кровообращения. Кардиоваскулярная терапия и профилактика. 2014;13 (2):4-11. doi: 10.15829/1728-8800-20142-4-11.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Богачев В.Ю., Голованова О.В., Кузнецов А.Н., Ершов П.В. Хронические заболевания вен нижних конечностей: современный взгляд на патогенез, лечение и профилактику. Режим доступа: https://medi.ru/info/4739/.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Кудыкин М.Н. Возможности терапии симптомов хронических заболеваний вен нижних конечностей. Стационарозамещающие технологии: Амбулаторная хирургия. 2019;(1-2):34-37. doi: 10.21518/1995-1477-2019-1-2-34-37.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Веселов Б.А. Клинико-экономическая эффективность мини-инвазивных методов лечения варикозной болезни нижних конечностей: дис.. канд. мед. наук (In Russ.) Available at: https://www.dissercat.com/content/kliniko-ekonomicheskaya-effektivnost-miniinvazivnykh-metodov-lecheniya-varikoznoi-bolezni-ni.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Богачев В.Ю. Хронические заболевания вен как проблема пациентов молодого возраста. Медицинский Совет. 2015;(4):62-66. doi: 10.21518/2079-701X-2015-4-62-66.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Jeanneret C., Jager K.A., Zaugg C.E., Hoffmann U. Venous reflux and venous distensibility in varicose and healthy veins. Eur J Vase Endovasc Surg. 2007;34 (2):232-242. doi: 10.1016/j.ejvs.2007.03.018.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Воронков А.В., Гамзелева О.Ю. Обзор современных флеботропных препаратов на основе флавоноидов как перспективных эндотелиопротекторов при лечении хронических заболеваний вен. Стационарозамещающие технологии: Амбулаторная хирургия. 2019;(1-2):27-33. doi: 10.21518/1995-1477-2019-1-2-27-33.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Garner R.C., Garner J.V., Gregory S., Whattam M., Calam A. Comparison of the absorption of micronized (daflon 500mg) and non micronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. Journal of Pharmaceutical Sciences. 2002;91 (1):32-40. doi: 10.1002/jps.1168.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Порембская О.Я., Косенко И.М. Фармакотерапия при хронических заболеваниях вен - как рационально выбрать флеботропный препарат? Флебология. 2018;(3):123-132. doi: 10.17116/flebo2018123123.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Silambarasan T., Raja B. Diosmin, a bioflavonoid reverses alterations in blood pressure, nitric oxide, lipid peroxides and antioxidant status in DOCA-salt induced hypertensive rats. Eur J Pharmacol. 2012;679 (1-3):81-89. doi: 10.1016/j.ejphar.2011.12.040.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Allaert F.A. Metaanalysis of the impact of the principal venoac-tive drugs agents on malleolar venous edema. Int Angiol. 2012;31 (4):310-315. Available at: https://www.minervamedica.it/en/jour-nals/international-angiology/article.php?cod=R34Y2012N04A0310.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Богачев В.Ю. Обзор Материалов Международного Флебологического Конгресса (Сан-Диего, США, 27-31 августа, 2003 год). Ангиология и Сосудистая хирургия. 2004;10 (2):54-59. Режим доступа: http://www.angiolsurgery.org/maga-zine/2004/2/8.htm.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Савельева М.И., Сычев Д.А. Возможности трансдермальных систем доставки лекарственных средств, применяемых при хронических заболеваниях вен. Флебология. 2018;12 (1):40-49. doi: 10.17116/flebo201812140-49.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Богачев В.Ю., Болдин Б.В., Туркин П.Ю. Современная терапия хронических заболеваний вен нижних конечностей: в фокусе - трансдермальные флеботропные препараты. РМЖ. 2018;6 (II):61-65. Режим доступа: https://www.rmj.ru/articles/</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Boitsov S.A., Samorodskaya I.V. Mortality and lost years of life as a result of cardiovascular premature deaths. Cardiovascular Therapy and Prevention. 2014;13(2):4-11. (In Russ.) doi: 10.15829/1728-88002014-2-4-11.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Bogachev V.Yu., Golovanova O.V., Kuznetsov A.N., Ershov P.V. Chronic venous diseases of the lower limbs: a modern view of pathogenesis, treatment and prevention. (In Russ.) Available at: https://medi.ru/info/4739/</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Kudykin M.N. Possibilities of treatment of symptoms of chronic diseases of lower limbs veins. Hospital-replacing technologies: Ambulatory surgery. 2019;(1-2):34-37. (In Russ.) doi: 10.21518/19951477-2019-1-2-34-37.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Veselov B.A. Clinical and economic efficiency of minimally invasive techniques in the treatment of varicose veins of lower extremities. Cand. of Sci. diss. (In Russ.) Available at: https:/ www.dissercat.com/content/kliniko-ekonomicheskaya-effektivnost-miniinvazivnykh-metodov-lecheniya-varikoznoi-bolezni-ni.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Bogachev V.Y. Chronic venous disease as a problem in young patients. Meditsinskiy sovet = Medical Council. 2015;(4):62-66. (In Russ.) doi: 10.21518/2079-701X-2015-4-62-66.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Jeanneret C, Jager K.A., Zaugg C.E., Hoffmann U. Venous reflux and venous distensibility in varicose and healthy veins. Eur J Vasc Endovasc Surg. 2007;34(2):232-242. doi: 10.1016/j.ejvs.2007.03.018.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Voronkov A.V., Gamzeleva O.Y. Review of modern phlebotrophic preparations based on flavonoids as perspective endothelioprotectors in the treatment of chronic diseases of the veins. Hospital-replacing technologies:Ambulatory surgery. 2019;(1-2):27-33. (In Russ.) doi: 10.21518/1995-1477-2019-1-2-27-33.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Garner R.C., Garner J.V., Gregory S., Whattam M., Calam A. Comparison of the absorption of micronized (daflon 500mg) and non micronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and angiologiya/Sovremennaya_terapiya_hronicheskih_zabolevaniy_ ven_nighnih_konechnostey_v_fokuse_transdermalynye_flebotropnye_preparaty/#.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Богачев В.Ю., Болдин Б.В., Туркин П.Ю., Лобанов В.Н. Местные препараты в лечении и снижении частоты развития нежелательных реакций после склеротерапии ретикулярных вен и телеангиэктазов. Ангиология и сосудистая хирургия. 2019;25 (4):102-107. Режим доступа: http/www.angiolsurgery. org/en/magazine/2019/4/10.htm. liquid scintillation counting. Journal of Pharmaceutical Sciences. 2002;91(1):32-40. doi: 10.1002/jps.1168.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Porembskaya O.Ya., Kosenko I.M. Pharmacotherapy of Chronic Venous Disease - How to Choose Appropriate Venoactive Drug? Flebologiya. 2018;(3):123-132. (In Russ.) doi: 10.17116/flebo2018123123.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Silambarasan T., Raja B. Diosmin, a bioflavonoid reverses alterations in blood pressure, nitric oxide, lipid peroxides and antioxidant status in DOCA-salt induced hypertensive rats. Eur J Pharmacol. 2012;679(1-3):81-89. doi: 10.1016/j.ejphar.2011.12.040.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Allaert F.A. Metaanalysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol. 2012;31(4):310-315. Available at: https://www.miner-vamedica.it/en/journals/international-angiology/article. php?cod=R34Y2012N04A0310.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Bogachev V.Yu. The review of materials of the international phlebologic congress (San Diego, USA August 27-31, 2003). Angiology and Vascular Surgery. 2004;10(2):54-59. (In Russ.) Available at: http://www.angiolsurgery.org/magazine/2004/2/8. htm.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Savel'eva MI, Sychev DA. Potential of the Transdermal Drug Delivery Systems for the Topical Treatment of Chronic Venous Diseases. Flebologiy". Journal of Venous Disorders. 2018;12(1):40-49. (In Russ.) doi: 10.17116/flebo201812140-49.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Bogachev V.Yu., Boldin B.V., Turkin P.Yu. Modern therapy of chronic venous diseases of the lower limbs: focus on transdermal phlebotropic drugs. RMJ = Russian Medical Journal. 2018;6(II):61-65. (In Russ.) Available at: https://www.rmj.ru/articles/angiologiya/ Sovremennaya_terapiya_hronicheskih_zabolevaniy_ven_nighnih_ konechnostey_v_fokuse_transdermalynye_flebotropnye_prepa-raty/#.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Bogachev V.Yu., Boldin B.V., Turkin P.Yu., Lobanov V.N. Local drugs in treating and decreasing the incidence of adverse reactions after sclerotherapy of telangiectasia. Angiology and Vascular Surgery. 2019;25(4):102-107. (In Russ.) Available at: http://www.angi-olsurgery.org/en/magazine/2019/4/10.htm.</mixed-citation></ref></ref-list></back></article>
